Reg-Galapagos To Acquire Cellpoint And Aboundbio To Accelerate Access To Next-Generation Cell Therapies

June 21 (Reuters) - Galapagos NV (GLPG.AS) : * REG-GALAPAGOS TO ACQUIRE CELLPOINT AND ABOUNDBIO TO ACCELERATE ACCESS TO NEXT-GENERATION CELL THERAPIES * GALAPAGOS NV - ALLCASH ACQUISITION OFCELLPOINT FOR UPFRONT AMOUNT OF EUR 125 MILLION, WITH MILESTONE PAYMENTS UP TO EUR 100 MILLION & ABOUNDBIO FOR $14 MILLION * GALAPAGOS - 2 PHASE 1/2A STUDIES IN RRNHL & RRCLL WITH CD19 CAR-T PRODUCT CANDIDATE CURRENTLY ONGOING, TOPLINE RESULTS EXPECTED IN H1 OF 2023

The copyright of this article belongs to the original author/organization.

The current content only represents the author’s point of view, and has nothing to do with the position of Longbridge. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by Longbridge, please contact: editorial@longbridge.global